Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS

@article{Methner2013MultipleSI,
  title={Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS},
  author={A. Methner and F. Zipp},
  journal={Nature Reviews Neurology},
  year={2013},
  volume={9},
  pages={72-73}
}
  • A. Methner, F. Zipp
  • Published 2013
  • Medicine
  • Nature Reviews Neurology
  • 2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified. 
    15 Citations

    Topics from this paper

    Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS
    • 8
    • PDF
    Thiamine Deficiency Promotes T Cell Infiltration in Experimental Autoimmune Encephalomyelitis: The Involvement of CCL2
    • 14
    • PDF
    LncRNA GAS5 inhibits microglial M2 polarization and exacerbates demyelination
    • 78

    References

    SHOWING 1-10 OF 11 REFERENCES
    Potassium channel KIR4.1 as an immune target in multiple sclerosis.
    • 312
    • PDF
    Insight into the mechanism of laquinimod action
    • 113
    Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    • 1,198
    • PDF
    Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.
    • 712
    • PDF
    Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    • 324
    • PDF
    Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    • 956
    Effects of dimethyl fumarate on neuroprotection and immunomodulation
    • 148
    T cells become licensed in the lung to enter the central nervous system
    • 287
    • PDF